

1 **H3K27me3-rich genomic regions can function as silencers to repress gene**
2 **expression via chromatin interactions**

3

4 Yichao Cai^{1,2*}, Ying Zhang^{1*}, Yan Ping Loh¹, Jia Qi Tng¹, Mei Chee Lim^{1,3},
5 Zhendong Cao^{1,4}, Anandhkumar Raju⁵, Erez Lieberman-Aiden⁶, Shang Li^{3,7},
6 Lakshmanan Manikandan⁵, Vinay Tergaonkar⁵, Greg Tucker-Kellogg^{2,8†}, Melissa
7 Jane Fullwood^{1,5,9†}

8

9 ¹Cancer Science Institute of Singapore, National University of Singapore, 14 Medical
10 Drive, 117599 Singapore.

11 ²Department of Biological Sciences, National University of Singapore, 16 Science
12 Drive 4, 117558 Singapore.

13 ³Cancer and Stem Cell Biology Programme, Duke-NUS Medical School, 8 College
14 Road, 169857 Singapore.

15 ⁴Department of Cancer Biology, Perelman School of Medicine, University of
16 Pennsylvania, Philadelphia, PA19104, USA.

17 ⁵Institute of Molecular and Cell Biology, Agency for Science, Technology and
18 Research (A*STAR), 61 Biopolis Drive, Proteos, 138673 Singapore.

19 ⁶Department of Genetics, Baylor College of Medicine, 1 Baylor Plaza, Houston,
20 TX77030, USA

21 ⁷Department of Physiology, Yong Loo Lin School of Medicine, National University of
22 Singapore, 2 Medical Drive, 117597 Singapore.

23 ⁸Computational Biology Programme, National University of Singapore, 6 Science
24 Drive 2, 117546 Singapore

25 ⁹School of Biological Sciences, Nanyang Technological University, 60 Nanyang
26 Drive, 637551 Singapore.

27

28

29

30

31

32

33 *These authors made equal and critical contributions

34 †Correspondence should be sent to:

35 (1) Melissa J. Fullwood, Cancer Science Institute Singapore (CSI) and School of
36 Biological Sciences, Nanyang Technological University, Email:
37 mfullwood@ntu.edu.sg; Telephone: (65) 6516 5381; Fax: (65) 6873 9664

38 (2) Greg Tucker-Kellogg, Department of Biological Sciences, National University
39 of Singapore. Email: dbsgtk@nus.edu.sg, Telephone: (65) 6516 4740

40

41 **Abstract**

42 Gene repression and silencers are poorly understood. We reasoned that
43 H3K27me3-rich regions (MRRs) of the genome defined from clusters of H3K27me3
44 peaks may be used to identify silencers that can regulate gene expression via
45 proximity or looping. MRRs were associated with chromatin interactions and interact
46 preferentially with each other. MRR component removal at interaction anchors by
47 CRISPR led to upregulation of interacting target genes, altered H3K27me3 and
48 H3K27ac levels at interacting regions, and altered chromatin interactions. Chromatin
49 interactions did not change at regions with high H3K27me3, but regions with low
50 H3K27me3 and high H3K27ac levels showed changes in chromatin interactions. The
51 MRR knockout cells also showed changes in phenotype associated with cell identity,
52 and altered xenograft tumor growth. MRR-associated genes and long-range
53 chromatin interactions were susceptible to H3K27me3 depletion. Our results
54 characterized H3K27me3-rich regions and their mechanisms of functioning via
55 looping.

57 **Introduction**

58 The 3-dimensional organization of our genomes is important for gene
59 regulation¹⁻³. The genome is organized into large Topologically-Associated Domains
60 (TADs) and chromatin interactions. Gene transcription is controlled by transcription
61 factors (TFs) that bind to enhancers and promoters to regulate genes⁴. TFs can bind
62 to proximal enhancers in the genome, and enhancers distal to genes can loop to
63 gene promoters via chromatin interactions to activate gene expression³. Cancer cells
64 show altered chromatin interactions^{2,3} including altered chromatin loops to key
65 oncogenes such as *TERT*⁵.

66 By contrast, mechanisms for gene repression are much less well understood.
67 Silencers are regions of the genome that are capable of silencing gene expression.
68 Silencers have been shown to exist in the human genome, but are less well
69 characterized than enhancers. Until now, there are only a few known experimentally
70 validated silencers that have been demonstrated to repress target genes *in vitro*,
71 such as the human synapsin I gene⁶, the human *BDNF* gene⁷ and human *CD4*
72 gene^{8,9} (experimentally validated silencer examples are discussed in Table S1). The
73 reason for the paucity of known silencers in the literature is that methods to identify
74 human silencer elements in a genome-wide manner are only starting to be
75 developed now. Moreover, the mechanism by which silencers can regulate distant
76 genes is still uncharacterized. Distant silencers are thought to loop over to target
77 genes to silence them^{10,11}, and this has been demonstrated in studies of polycomb-
78 mediated chromatin loops in *Drosophila*¹² and in mice¹³, but no such examples have
79 been characterized to date in humans.

80 Polycomb Group (PcG) proteins including Polycomb Repressive Complexes,
81 PRC1 and PRC2 are widely recognized to mediate gene silencing of developmental
82 genes¹⁴. During the development process, PRC1 and PRC2 have the ability to
83 orchestrate genome architecture and repress gene expression¹⁵. There are two
84 different types of genomic domains: active domains and repressive domains, which
85 to regulate gene expression and construct cellular identity. Genes involved in cell
86 self-renewal are contained within the active domains which are governed by super-
87 enhancers, while genes specifying repressed lineage are organized within chromatin
88 structures known as PcG domains¹⁶. Moreover, intact PcG domains have been
89 shown to be necessary to maintain the chromatin interaction landscape^{17,18}.

90 However, the mechanisms of PcG domain formation and PcG proteins recruitment
91 are not fully characterized yet¹⁹, which makes finding silencers more difficult.

92 PcG domains are marked by H3K27me3, which is deposited by the catalytic
93 component of PRC2 complex, mainly Enhancer of zeste homolog 2 (EZH2) and
94 sometimes EZH1²⁰. H3K27me3 marks are associated with gene repression for cell
95 type-specific genes. Unlike H3K9me3 which remains silenced all the time and
96 prevents multiple TFs from binding²¹, H3K27me3 still allows these genes to be
97 activated through TF binding in a different cell state²². H3K27me3 is known to be a
98 characteristic of silencers^{18,23}. Although large blocks of H3K27me3-marked loci have
99 been observed in previous studies²⁴⁻²⁶, their regulatory actions and roles in
100 chromatin loops were not explored in these manuscripts.

101 Recently, several studies have proposed methods to identify silencer
102 elements in a genome-wide manner. Huang *et al* defined silencers using the
103 correlation between H3K27me3-DNase I hypersensitive site (DHS) and gene
104 expression²⁷. At the same time, Jayavelu *et al* used a subtractive analysis approach
105 to predict silencers in over 100 human and mouse cell types²⁸. Moreover, Pang and
106 Snyder identified silencers through an innovative “ReSE screen” which screened for
107 genomic regions that can repress caspase 9 expression upon apoptosis induction²⁹.
108 Interestingly, Ngan *et al* characterized silencers in mouse development through
109 PRC2 Chromatin Interaction Analysis with Paired-End Tag sequencing (ChIA-PET)
110 in mouse embryonic stem cells. They concluded that PRC2-bound looping anchors
111 function as transcriptional silencers suggesting that we can identify silencers through
112 investigating chromatin interactions¹³.

113 However, there is no consensus yet in terms of how to identify silencers.
114 Notably, each of these methods identify different genomic regions as silencers,
115 raising the question of whether there may be different classes of silencers.
116 Moreover, current methods for identifying silencers are laborious and require
117 complicated bioinformatics analyses and/or genome-wide screening (Table S2,
118 “comparison of different human silencer identification methods”). A simple, easy to
119 perform method to identify silencers in the genome in a high-throughput manner
120 would be ideal. Further investigation is needed to understand whether there are
121 different classes of silencers and to characterize the roles of silencers in the
122 genome.

123 The term “super-enhancer”³⁰ has been used to describe clusters of H3K27ac
124 peaks which show very high levels of H3K27ac or other transcription-associated
125 factors such as mediators as determined from ChIP-Seq data. Super-enhancers
126 have high levels of chromatin interactions to target genes³¹, and are associated with
127 oncogenes in cancer cells³² and cell fate-associated genes in embryonic stem
128 cells³³. While more research needs to be done to determine if super-enhancers are a
129 distinctly different entity from enhancers, super-enhancers are thought as strong
130 enhancers, and the definition has been useful in identifying genes important for cell-
131 type specification³⁴.

132 Here, we reasoned that we can similarly identify “super-silencers” or
133 “H3K27me3-rich regions (MRRs)” from clusters of H3K27me3 peaks in the genome
134 through ChIP-Seq on H3K27me3. We hypothesized that H3K27me3-rich regions
135 may be a useful concept in identifying genomic regions that contain silencers which
136 can repress target genes either in proximity or via long-range chromatin interactions.
137 The target genes may be tumor suppressors in cancer cells, and also cell fate-
138 associated genes that need to be turned off for differentiation to occur.

139 We found several hundred MRRs in the K562 chronic myelogenous leukemia
140 cell line, which showed dense chromatin interactions to target genes and to other
141 MRRs. Next, we experimentally validated two looping silencers through CRISPR
142 mediated removal, and both showed upregulation of target genes indicating that they
143 are indeed *bona fide* silencers. Through CRISPR excision of one of the *IGF2* looping
144 silencer components and one of the *FGF18* looping silencer components, we found
145 that silencers control cell identity as their removal caused cell identity changes.
146 Using the silencer at *IGF2* as an example, we dissected the consequences of
147 silencer removal through 4C and ChIP-Seq with H3K27me3 and H3K27ac. We found
148 that removal of a component of a silencer by CRISPR excision leads to changes in
149 chromatin loops. Remarkably, regions that originally presented with very high
150 H3K27me3 levels were stable in terms of chromatin loops while chromatin
151 interactions to regions with low H3K27me3 and high H3K27ac levels changed.
152 Moreover, genes in close proximity to, and genes that loop to MRRs by long-range
153 chromatin interactions, were more susceptible to EZH2 inhibition. These genes
154 showed higher levels of upregulation upon EZH2 inhibition, as compared with genes
155 in close proximity or which loop to typical H3K27me3 peaks. EZH2 inhibition led to
156 changes in long-range chromatin interactions at MRRs.

157 Taken together, our results indicated that clustering of H3K27me3 peaks in a
158 manner similar to the super-enhancer analyses can identify MRRs that contain
159 silencers that can loop over to target gene promoters. Silencer perturbation by
160 H3K27me3 depletion and CRISPR excision led to epigenomic, transcriptomic and
161 phenotypic consequences.

162

163 Results

164

165 Identification and characterization of H3K27me3-rich regions (MRRs) in the 166 human genome

167 We identified highly H3K27me3-rich regions (MRRs) from cell lines using
168 H3K27me3 ChIP-seq data³⁵ in the following manner: we first identified H3K27me3
169 peaks, then clustered nearby peaks, and ranked the clustered peaks by average
170 H3K27me3 signals levels. The top clusters with the highest H3K27me3 signal were
171 called as “H3K27me3-rich regions” (MRRs) and the rest were called as “typical
172 H3K27me3” regions (Figure 1A, 1B). The peaks that were merged together during
173 this process were called constituent peaks. This method is similar to how super-
174 enhancers were defined^{33,36}. Recently, Pang and Snyder identified a list of silencer
175 elements in K562 cells using a lentiviral screening system called ReSE²⁹. We
176 overlapped our list of MRRs in K562 with the list of silencers that identified by ReSE
177 and found that 10.66% of ReSE silencer elements overlap with our MRRs (Figure
178 1C). This overlap percentage of 10.66% between our MRR and the ReSE silencer
179 elements is significantly higher when compared to random expectation (Figure 1C).
180 Although typical H3K27me3 peaks also have more overlap when compared with
181 expectation, the differences in the percentage between actual and expected overlap
182 percentage are larger for MRR (Figure 1C). This indicated that MRRs can be used to
183 identify silencers in the genome. While the overlap percentage between our MRR
184 and ReSE silencer elements is higher than random expectation, it is still relatively
185 low compared with the total number of ReSE elements, which could be because
186 ReSE elements contain other types of silencers such as DNA hypomethylated
187 regions.

188 The number of constituent peaks and overlapping genes at MRRs is larger
189 than typical H3K27me3 peaks (Figure S1A, S1B). Considering the differences in the
190 lengths of MRRs and typical H3K27me3 peaks, we used constituent peaks of MRRs
191 and typical H3K27me3 peaks to study CpG methylation and gene features. The
192 results showed that the constituent peaks of MRRs and typical H3K27me3 peaks
193 mostly overlap with inter CpG island methylation (Figure S1C) and the intronic
194 regions of genes (Figure S1D).

195 Many MRR-overlapping genes in different cell lines are known or predicted
196 tumor suppressor genes³⁷ (Figure S1E). For example, *NPM1*, the most commonly
197 mutated gene in leukemia³⁸⁻⁴¹, overlaps with an MRR in the leukemic cell line K562.
198 *FAT1*, which is frequently mutated in chronic lymphocytic leukemia (CLL) and can
199 act as a tumor suppressor through inhibiting Wnt signaling^{42,43}, also overlaps with an
200 MRR in K562. Gene ontology analysis showed that MRR-related genes are enriched
201 in developmental and differentiation processes, while genes associated with typical
202 H3K27me3 peaks are enriched in cell metabolism and transportation processes
203 (Figure S1F, S1G). These results suggested that MRR may regulate important
204 genes related to development and tumorigenesis.

205 ChIP-seq signals of EZH2 showed high correlation with H3K27me3 signal at
206 typical H3K27me3, MRRs, constituent peaks of typical H3K27me3 and constituent
207 peaks of MRRs, which is consistent with EZH2's role in H3K27me3 mark deposition
208 (Figure 1C; Figure S1H, S1I). Notably, the constituent peaks of MRRs had higher
209 H3K27me3 and EZH2 signals than the constituent peaks of typical H3K27me3 peaks.
210 This suggests that there are genomic regions with higher level of H3K27me3 and
211 EZH2 compared with others, and they can be found in MRRs. In addition, the ChIP-
212 seq profiles of SUZ12 and BMI1 are also higher in the constituent peaks of MRRs,
213 suggesting that these regions may be targeted by PRC1 and PRC2 complex (Figure
214 S1J, S1K).

215 MRRs were different in different cell lines, where a same gene can overlap
216 with different types of peaks (Figure S1L – S1N). For example, the cadherin-like
217 coding gene *CPED1* is covered by a broad MRR in GM12878, but overlaps with a
218 super-enhancer in K562 (Figure S1L). Conversely, the gene for *DENND2D* is
219 associated with an MRR but overlaps with a super-enhancer in GM12878 (Figure
220 S1L). In addition, most MRRs were unique to individual cell lines (Figure S1O).

221 Analysis of cell line expression data showed that genes which are MRR-
222 associated in one cell line, but H3K27ac peak-associated in a second cell line were
223 upregulated in the second cell line, while genes that are super enhancer-associated
224 in one cell line but are H3K27me3 peak-associated in a second cell line were down-
225 regulated in the second cell line (Figure 1E). This observation is consistent with
226 previously identified elements with dual function in both enhancing and silencing in
227 mouse, human⁴³, and *Drosophila*⁴⁴. The expression fold changes between
228 repressive and active state are higher than those genes that merely lost MRR or SE
229 (Figure 1E; MRR vs. others and SE vs. others) or gained H3K27ac or H3K27me3
230 (Figure 1E; others vs. H3K27ac and others vs. H3K27me3), respectively. Further,
231 genes whose expression were more cell line-specific were associated with more
232 MRRs than those genes with lower expression specificity (Figure S1P). The
233 uniqueness and specificity of MRRs suggested they might be primed for specific
234 regulation in different contexts.

235 We overlapped MRRs with high-resolution *in situ* Hi-C data⁴⁵, and found that
236 constituent peaks of MRRs had a higher density of chromatin interactions than the
237 constituent peaks of typical H3K27me3 peaks in both K562 and GM12878 (Figure

238 1F; Figure S1Q, S1R). The involvement of chromatin interactions in MRRs was
239 similar to super-enhancers compared with typical enhancers⁴⁶, which suggested that
240 chromatin interactions might be important within regions rich in histone modification.

241 In summary, we defined MRRs using H3K27me3 ChIP-seq peaks, and
242 showed that MRRs might be involved with specific gene repression related to
243 development, differentiation and cancer via chromatin interactions.

244 **H3K27me3-rich regions (MRRs) preferentially associate with MRRs in the** 245 **human genome via chromatin interactions**

246 We assigned chromatin states at Hi-C interaction anchors using H3K27me3
247 and H3K27ac peaks: active (A) anchors overlap with H2K27ac peaks, repressive (R)
248 anchors overlap with H3K27me3 peaks, bivalent (B) anchors overlap with both
249 H3K27me3 and H3K27ac peaks, and quiescent (Q) anchors overlap with neither
250 peak (Figure 2A). We further defined the chromatin state pair of an interaction as the
251 chromatin states of its anchors and calculated the proportion of different chromatin
252 interaction in the Hi-C data (Figure 2B, "Obs"). Next, we calculated the expected
253 proportion of interactions for each state pair under a homogeneous model (Figure 2B,
254 Exp), and compared those expectations to the actual number of observations (Figure
255 2B, $\log_2(\text{Obs}/\text{Exp})$ on the x-axis). If the observed proportion of a certain category of
256 interactions were more frequently seen, the $\log_2(\text{Obs}/\text{Exp})$ value would be positive;
257 conversely, if a certain category was depleted, the $\log_2(\text{Obs}/\text{Exp})$ value would be
258 negative.

259 Interactions between anchors of the same state (AA, RR, and BB) were more
260 likely to interact with each other, while interactions with vastly different chromatin
261 state pairs (e.g., AR, BQ) less likely (Figure 2B, left), regardless of cell line. When
262 grouped into typical H3K27me3 peaks (T) versus high H3K27me3 regions or MRRs
263 (MRR), the high H3K27me3 regions showed a preference for interactions with other
264 MRRs (Figure 2B, right). In keeping with A/B chromatin compartments of the nucleus,
265 this 'like-like' preference indicated that loci of similar chromatin state were more
266 prone to interact with each other.

267 To further explore the potential regulatory role of MRRs in chromatin
268 interactions, we identified the subset of MRR-anchored interactions where at least
269 one anchor peak overlapped a gene transcription start site, and grouped them
270 according to whether the MRR anchor was proximal or distal to the TSS anchor
271 (Figure 2C, 2D; Figure S2A-S2F, S2G; examples of genes can be found in Figure
272 S2I-S2L). Both proximal and distal gene looping occur for MRR-anchored
273 interactions, but some MRRs are large enough that both anchors occur in the same
274 MRR. While proximal looping genes are a subset of the genes within MRRs, distal
275 looping genes are only identified by chromatin interactions (Figure 2D, right panel).
276 The expression of genes that are proximally, distally, or internally associated with
277 MRR are lower than randomly sampled genes that are involved in chromatin
278 interactions (Figure 2E; Figure S2H). The difference in gene expression levels
279 between proximal, distal, and internal categories is not significant, suggesting that
280 distal looping by MRRs is associated with reduced gene expression to a similar
281 extent as proximal regulation by MRRs (Figure 2E). There is no significant difference
282 between proximal, distal and internal categories, thus showing that genes regulated
283 by distal looping may be silenced to the same extent as genes proximal to MRRs.
284 This indicated the importance of long-range looping in mediating silencing between
285 distal regulatory elements and gene promoters. The top-ranking MRRs are often
286 involved in extensive internal looping (Figure S2K-S2L). Gene ontology analysis

287 showed that MRR-associated genes in the context of chromatin interactions are
288 involved in developmental and differentiation processes (Figure S2M).

289 In order to validate the 'like-like' preference of chromatin interactions, we
290 performed Circular Chromosome Conformation Capture (4C) experiments on
291 selected loci at MRR to investigate the associated chromatin interactions in a
292 comprehensive and high-resolution manner. We annotated the interactions based on
293 the chromatin state of the anchor distal from the bait in K562 (Figure 2F and Figure
294 S2N-P), and across multiple cell lines (Figure S2Q-R). The interaction profiles of 4C
295 baits of different states were largely dominated by interacting regions of the same
296 state as the baits. In addition, the *TMCO4* 4C data showed that most 4C interactions
297 fell within the same MRR as the bait and only a handful of them were outside of the
298 MRR. This suggested that MRR can have extensive internal looping.

299 We also carried out 4C experiments on the same bait across different cell
300 lines. The interactions and the chromatin state at the bait locus varied in different cell
301 lines, but the interaction profile maintained a preference for the same chromatin state
302 as the bait (Figure S2Q, S2R). As a further test of this concept, the extensive BB
303 long-range interactions (green arcs) connecting *PSMD5* and *TOR1A* in K562 were
304 validated using reciprocal 4C bait design. When the *PSMD5* bait region was A
305 (active) in either GM12878 or HAP1 cells, the BB interactions were largely reduced
306 and other types of interactions started to appear (Figure S2Q).

307 Next, we analyzed the transcription factors binding to the regions of MRRs
308 that are connected by chromatin interactions. ChIP-seq peaks of chromatin
309 architectural proteins (CTCF, YY1, ZNF143), cohesin subunits (RAD21, SMC3), and
310 transcription repression-associated proteins (EZH2, REST, GATAD2B) were
311 downloaded from ENCODE and overlapped with the interacting regions of MRRs,
312 which were then normalized to Z-score and clustered by hierarchical clustering.
313 Specific enrichments of one specific transcription factor can be found in several
314 small clusters (Figure 2G; YY1 in cluster_1, EZH2 in cluster_2, and SMC3 in
315 cluster_3). Another cluster was identified with very high binding affinity of RAD21,
316 REST, ZNF143, CTCF, and SMC3 (Figure 2G cluster_5). Our results demonstrated
317 that different chromatin architectural proteins are involved in the regulation of
318 different silencer-associated chromatin interactions.

319

320 **CRISPR excision of a looping anchor within an MRR (MRR1-A1) leads to**
321 **upregulation of multiple genes like *FGF18*, cell differentiation and tumor**
322 **growth inhibition**

323 Next, we asked if MRRs function as silencers to regulate gene expression.
324 We selected 2 MRRs for functional testing based on the H3K27me3 signal, the
325 presence of Hi-C anchors and the number of Hi-C anchors they associated with
326 whether the genes were involved in cell identity (Supplementary Text). Briefly, there
327 are 974 MRRs in K562 (Figure S3A) and of those MRRs, 237 MRRs are associated
328 with genes. Among these, 130 MRRs show proximal looping to genes (MRRs
329 overlap with target gene promoters), 111 MRRs show distal looping to genes (MRR
330 loops over to the promoter of target gene by long-range chromatin interactions) and
331 51 MRRs show internal looping to genes (part of the MRR overlaps with the target
332 gene promoter and the other part of the MRR loops over to the promoter of the target
333 gene by long-range chromatin interactions). From this list, we selected MRR1, an
334 internal looping example which showed 2 Hi-C loops to *FGF18*, a fibroblast growth
335 factor involved in cell differentiation and cell-to-cell adhesion^{47,48} (Figure 3A) and
336 MRR2, an internal looping example which showed 3 Hi-C loops to *IGF2*, an

337 imprinted gene known to be associated with genomic silencers⁵⁰ and involved in
338 growth, development and cancer⁴⁹ (Figure 5A).

339 We designed the CRISPR deletion site at a 1 kb region in MRR1 (termed
340 “MRR1-A1”) located in the *FBXW11* intronic region that was associated with one of
341 two Hi-C anchors that loop over to *FGF18* (Figure 3A). This region has high
342 H3K27me3 as validated by ChIP-qPCR (Figure S3B). MRR1-A1 is part of cluster_8
343 (associated with low levels of cohesin proteins, high binding to GATAD2B; Table S8)
344 from Figure 2G. We performed 4C using MRR1-A1 as the bait to detect all the
345 genomic locations that have chromatin interactions with this region in wild-type K562.
346 The 4C-seq results showed that this region indeed had chromatin interactions with
347 *FGF18* and several other genes such as *NPM1* and *UBTD2* (Figure 3A).

348 Next, we performed CRISPR deletion and generated three knock out (KO)
349 clones (Figure S3C). To scan for target genes, we prepared RNA-seq from one KO
350 clone and aligned this data with the 4C-seq data using MRR1-A1 as the bait (Figure
351 3A). From RNA-seq fold changes of MRR1-A1 looping genes, we found upregulation
352 of *FGF18* and *UBTD2* (Figure 3B, Figure SD). For proximal genes, we found
353 upregulation of genes including *SH3PXD2B* and *C5ORF58* (Figure 3C, Figure S3E).
354 Among those genes, upregulation of the *FGF18* was further confirmed by RT-qPCR
355 consistently in three different KO clones (Figure 3D) while *UBTD2* was upregulated
356 significantly in KO1 but not in other clones. Therefore, we focused on *FGF18* gene
357 for further analysis.

358 Next, we treated the K562 cells with GSK343 (EZH2 methyltransferase
359 inhibitor). Upon GSK343 treatment, *FGF18* gene was upregulated compared with
360 DMSO control. This indicates that *FGF18* gene was upregulated upon H3K27me3
361 depletion. By contrast, in MRR1-A1 KO clones treated with GSK343, *FGF18* was
362 upregulated to a much smaller extent as compared with wild-type cells (Figure 3E).
363 This indicates that *FGF18* gene upregulation upon H3K27me3 depletion is partially
364 dependent on intact MRR1-A1, which further suggested that MRR1-A1 is a silencer.

365 To explore if the MRR1 is cell type specific, we identified MRRs in seven cell
366 lines and found that MRR1 is specific to two of the seven cell lines, K562 and
367 GM12878 (Figure S4B) which suggested that silencers are specific to different cell
368 types and might control the cell identity related genes.

369 Since *FGF18* has been reported to be involved in cell-to-cell adhesion^{47,48},
370 next we asked if KO clones showed changes in adhesion. To address this, we
371 performed gene ontology (GO) analysis which showed that KO clones may undergo
372 cell adhesion and cell differentiation (Figure 3F). First, we observed that the KO
373 clones show increased adhesion to the cell culture plate surface and formed
374 aggregates while wild type cells remained as suspension cells (Figure 4A). The
375 adhesion ability was further quantified by cell adhesion assays (Figure 4B).

376 Next, because *FGF18* is associated with differentiation^{47,48}, we investigated
377 whether KO clones showed an erythroid differentiation phenotype. Cellular
378 aggregates were reported by several publications^{51,52} to be associated with cell
379 differentiation such as erythroid and megakaryocyte lineage of K562 cells. Therefore,
380 we checked the expression of haemoglobin genes which can be the indicator of
381 erythroid lineage differentiation⁵³ in the RNA-seq data and further confirmed some of
382 their upregulation (*HBB*, *HBZ* and *HBE1*) by RT-qPCR (Figure 4C).

383 To investigate whether the differentiation phenotype might be partially caused
384 by upregulation of *FGF18*, we performed siRNA knock down targeting *FGF18* gene
385 in the KO clones, which led to 60%-80% reduction in *FGF18* gene expression levels.
386 Haemoglobin genes can be partially rescued by *FGF18* knocking down (Figure S4A)

387 which suggested that erythroid differentiation partially caused by *FGF18* upregulation
388 (Figure 4F). We speculate that *FGF18* siRNA knockdown did not lead to a complete
389 rescue because MRR1-A1 knockout also upregulates other genes in addition to
390 *FGF18*. For example, *SH3PXD2B* may also play roles in controlling erythroid
391 differentiation⁵⁴.

392 Leukemic cell differentiation induction is associated with cell growth inhibition
393 and small molecule inhibitors such as All-*trans* Retinoic Acid (ATRA) that can induce
394 differentiation have been useful in treatment of Acute Promyelocytic Leukemia,
395 suggesting that methods to induce differentiation could lead to potential leukemia
396 treatments^{53,55}. Therefore, we asked if silencer removal is associated with growth
397 inhibition *in vivo*, given that silencer removal leads to cell differentiation. To test this,
398 we performed xenograft experiments for two different KO clones and both two KO
399 clones showed inhibition of tumor growth in the mice (Figure 4D and 4E). This tumor
400 growth inhibition suggested that MRR1-A1 might play tumor suppressor roles in
401 leukemia and suggests the possibility that silencers can control cell identity through
402 repression of tumor suppressor gene expression. In summary, our analyses
403 suggested that MRR1-A1 can function as a looping silencer of *FGF18* as well as
404 other genes and MRR1-A1 removal leads to cell identity changes such as cell
405 adhesion, cell differentiation and tumor growth inhibition (Figure 4F).

406

407 **CRISPR excision of a looping anchor within an MRR (MRR2-A1) leads to** 408 **multiple gene upregulation including *IGF2*, cell differentiation and tumor** 409 **growth inhibition**

410 MRR2 was characterized in the same manner as MRR1. Specifically, we
411 designed another 1 kb deletion in MRR2 (termed “MRR2-A1”) located in an
412 intergenic region 10 kb away from the long non-coding RNA *H19* that was
413 associated with one of three Hi-C anchors looping over to *IGF2* (Figure 5A). High
414 H3K27me3 signal of MRR2-A1 was confirmed by ChIP-qPCR (Figure S5A) and
415 chromatin interactions to *IGF2* and other genes were confirmed by 4C-seq (Figure
416 5A). The MRR2-A1 anchor was in cluster_5 in Figure 2G, and it has high binding
417 affinity of CTCF, RAD21, SMC3 and REST (Table S8).

418 RNA-seq of one MRR2-A1 KO clone (Figure S5B) showed upregulation of
419 multiple genes which loop to MRR2-A1 (looping genes) including *LSP1*, *ASCL2* and
420 *TSSC4* (Figure 5B, Figure S5C). For proximal genes, *MUC2*, *H19* and *C11ORF21*
421 were upregulated in KO (Figure 5C, Figure S5D). H3K27me3 and H3K27ac ChIP-
422 seq of this KO also showed changes in H3K27me3 and H3K27ac levels around
423 MRR2 (Figure S5F). *IGF2* is expressed at a very low level in differentiated cells of
424 the haematopoietic lineage⁵⁶ and detected at very low levels by RNA-seq and
425 therefore not shown in the fold change calculation. As *IGF2* has been previously
426 shown to be regulated by silencers via chromatin interactions in mice¹³, we asked
427 whether RT-qPCR could detect *IGF2* in our clones. Using RT-qPCR, we could detect
428 *IGF2* and we found that *IGF2* was upregulated in all three KO clones (Figure 5D). By
429 contrast, *H19* was upregulated in one of the three KO clones as measured by RT-
430 qPCR (Figure S5E). This indicated MRR2-A1 can function as a looping silencer to
431 repress *IGF2* in human K562 cells. Again, *IGF2* was upregulated upon GSK343
432 treatment and the level of upregulation was reduced by MRR2-A1 removal, which
433 showed that MRR2-A1 is a silencer (Figure 5E). Similar to MRR1, MRR2 was also
434 cell type specific (Figure S5I).

435 Through gene ontology (GO) analysis of the RNA-Seq on the MRR2-A1 KO
436 clone, we found the term “cell differentiation” (Figure 5F). Thus, we asked if these

437 KO clones also undergo erythroid differentiation. RT-qPCR showed the haemoglobin
438 genes (*HBB*, *HBZ* and *HE1*) were upregulated in the KO clones (Figure 5G) and
439 *IGF2* siRNA knock down can partially reduce this upregulation (Figure S5G) which
440 suggests the differentiation was partially caused by *IGF2* upregulation in MRR2-A1
441 KO clones (Figure S5H). Similar to *FGF18* siRNA knockdown, we did not see a
442 complete rescue of the differentiation phenotype by *IGF2* siRNA, which we also
443 speculate might be because MRR2-A1 also upregulates other genes besides *IGF2*.

444 Finally, we tested to see whether the CRISPR KO clones showed tumor
445 growth inhibition *in vivo*, similar to MRR1. Xenograft experiments showed severe
446 tumor growth inhibition of two different clones (Figure 5H) which further suggests
447 that silencers can control cancer growth. Therefore, this MRR2-A1 example together
448 with MRR1-A1 example confirmed the existence of two looping silencers and
449 showed that looping silencers are involved in the control of cell identity and tumor
450 growth.

451

452 ***IGF2* looping silencer (MRR2-A1) removal caused changes of distant** 453 **chromatin interactions**

454 Through the previous two examples, we confirmed the existence of looping
455 silencers and demonstrated they can control cell identity. Next, we investigated the
456 epigenomic consequences of a looping silencer removal using the *IGF2* looping
457 silencer (MRR2-A1) example. First, we asked whether chromatin interaction
458 landscape will be changed upon looping silencer removal. We performed 4C-seq in
459 the KO and control clones. Using *IGF2* as the bait, we detected there are 33
460 chromatin interactions lost and 12 chromatin interactions gained after MRR2-A1
461 knocking out while a control bait remains highly unchanged (Figure 6A, Figure S6A).
462 Several lost loops were confirmed by 3C-PCR (Figure S6B) which indicates that
463 looping silencer removal could lead to alterations in the chromatin interaction
464 landscape.

465 Next, we classified chromatin interactions into three types: unchanged loops,
466 gained loops and lost loops to explore their features. Through mapping their distance
467 and density, we found that the average distance of changed loops are greater than
468 unchanged loops which indicates that the long-range chromatin interactions which
469 are further away to the bait tend to change (Figure 6B). Moreover, the long-range
470 chromatin interactions have a greater propensity to be lost than to be gained. Given
471 that long-range chromatin interactions require more energy to be held together⁵⁷, we
472 speculated that when an anchor is lost, the amount of energy present in the system
473 to hold together the long-range chromatin interactions may not be sufficient.

474

475 **Integrative analysis of histone modification states and chromatin interactions** 476 **before and after *IGF2* looping silencer (MRR2-A1) removal**

477 MRR2 has high H3K27me3 signals and histone modifications may play a key
478 role in *IGF2* upregulation. Therefore, we performed H3K27me3 and H3K27ac ChIP-
479 seq in the KO and control clones (Figure S6C). We found that H3K27me3 decreased
480 along *IGF2* gene region upon knockout (Figure 6C) while a control region remained
481 similar (Figure S6D). This suggested that silencer removal will cause H3K27me3
482 loss at the target gene region.

483 Next, we performed integrative analysis of 4C-seq and ChIP-seq. Surprisingly,
484 we found that the initial histone states of the cells before knockout were associated
485 with whether the chromatin interactions would be gained, lost or unchanged upon
486 knockout of MRR2-A1 (Figure 6D). Specifically, very repressed loops with high

487 H3K27me3 in control cells were unchanged or lost after KO. Loops with high
488 H3K27ac and loops with low H3K27me3 in control cells tend to be easily changed
489 either gained or lost after KO (Figure 6D).

490 Moreover, when we compared the integrative analysis in EV and KO, we
491 observed significant decrease in H3K27me3 for unchanged loops while levels
492 H3K27ac increased slightly (Figure 7A-B) which suggested that the repressive ability
493 of the chromatin interaction became weaker and all the chromatin interactions
494 looping to *IGF2* became more active in terms of histone state after MRR2-A1 KO. An
495 example of the unchanged loops is shown in Figure 7C, which displays unchanged
496 loops to *IGF2* promoter along with decreased H3K27me3 levels in KO. When
497 examining the gained loops to *IGF2* gene, we observed increase in H3K27ac and no
498 change in H3K27me3 (Figure 7A-B) indicating that *IGF2* promoter could also gain
499 more active loops to activate gene expression. An example of the gained loops is
500 shown in Figure 7D.

501 Taken together, the regions that loop to *IGF2* in the KO clones are now more
502 active with higher H3K27ac and lower H3K27me3 levels. These findings
503 demonstrate two mechanisms by which *IGF2* might be upregulated in KO clones.
504 First, *IGF2* showed gain of chromatin loops to more active anchors and losses of
505 loops to several repressive anchors. Second, the retained loops which had strong
506 H3K27me3 levels at the control cells became weaker after KO (Figure 7E). A
507 combination of these mechanisms may operate in different cellular and physiological
508 contexts.

509

510 **MRR-associated gene expression and long-range chromatin interactions are** 511 **susceptible to EZH2 perturbation**

512 In order to investigate the effects of H3K27me3 on MRR-associated
513 chromatin interactions and associated gene expression, we eliminated or reduced
514 H3K27me3 by EZH2 inhibitor treatment (GSK343) in K562 cells and CRISPR
515 mediated knockout of EZH2 in HAP1 cells (a near haploid cell line derived from
516 chronic myeloid leukemia).

517 After treatment with GSK343 in K562 cells, the levels of H3K27me3
518 decreased globally, leading to the loss of nearly half of the H3K27me3 ChIP-seq
519 peaks (Figure 8A). However, there were still residual H3K27me3 peaks after
520 GSK343 treatment, and these were the regions that had higher H3K27me3 signal
521 before the treatment as compared with the susceptible peaks. Western blot
522 confirmed that 1 μ M of GSK343 treatment in K562 cells and EZH2 knockout in HAP1
523 cells were sufficient to lead to global loss of H3K27me3 (Figure S7A-B).

524 To interrogate the gene expression changes of MRR-related genes, we
525 performed RNA-seq in DMSO-treated and 5 μ M GSK343-treated K562 cells. The
526 RNA-seq results indicated strong upregulation of H3K27me3-associated genes,
527 while genes associated with H3K27ac peaks (super enhancers or typical enhancers)
528 underwent minimal net change (Figure 8B). Notably, MRR-associated genes were
529 the most strongly upregulated as compared with other categories (typical H3K27me3,
530 super-enhancer and typical enhancers) (Figure 8B). Similarly, a lower dose of 1 μ M
531 GSK343 treatment in K562 and EZH2 knockout in HAP1 also induced H3K27me3
532 depletion and significant upregulation of MRR-associated genes as compared with
533 other categories (Figure S7C-E). In addition, cell adhesion related genes in RNA-seq
534 of HAP1 and K562 cells were significantly upregulated (Figure S7F-S3I). This is in
535 concordance with the increased aggregation HAP1 *EZH2* KO cells (Figure S7J).
536 HAP1 *EZH2* KO cells also expressed slower growth rate compared with EZH2 WT

537 cells (Figure S7K), possibly due to contact inhibition of the cells. Taken together, our
538 results showed that MRR-associated genes were highly susceptible to EZH2
539 inhibition and cell adhesion pathways were upregulated.

540 To further understand the chromatin interactions changes after EZH2
541 inhibition treatment, we also performed 4C and ChIP-seq experiments and
542 investigated our candidate genes used in the CRISPR KO experiments in more
543 detail. ChIP-seq data at *FGF18* gene showed that H3K27me3 level was decreased
544 and there were accompanied lost peaks, while the H3K27ac and H3K4me3 signal
545 were mostly unaltered (Figure 8C). By comparing the 4C interactions at *FGF18*
546 promoter in DMSO and GSK343 condition, we found that long-range 4C interactions
547 were altered (Figure 8D), while short-range 4C interactions were almost unchanged
548 (Figure 8E). Density plot showed that the unchanged 4C interactions have a closer
549 distance relative to the 4C bait compared with gained or lost categories (Figure 8F).
550 We also performed 4C experiments in 5 μ M treated GSK343 K562 cells using MRR1-
551 A1, *IGF2*, and MRR2-A1 as baits, and their interaction profiles showed that short-
552 range interactions are mostly unchanged (Figure S7L-M). To compare the effects of
553 different drug concentrations, we performed all the 4C experiment using same baits
554 (*FGF18*, MRR1-A1, *IGF2*, and MRR2-A1) in 1 μ M treated GSK343 K562 cells. The
555 4C interaction profiles in 5 μ M and 1 μ M treated GSK343 K562 cells were very similar
556 (Figure S7N).

557 In addition, we performed 4C experiments using other baits in 1 μ M treated
558 GSK343 K526 cells and EZH2 KO HAP1 cells which show the same conclusion that
559 the short-range chromatin interactions in the vicinity of the 4C baits were largely
560 unchanged (Figure S7O-R). By contrast, the long-range chromatin interactions tend
561 to change. One question is whether the changing long-range chromatin interactions
562 in H3K27me3 perturbed cells is due to changing numbers of cells displaying
563 chromatin interactions or if it is due to changing chromatin interaction intensities. As
564 the HAP1 cell line is near-haploid, there will just be one copy of a particular gene
565 locus, and a change in the level of chromatin interactions would not be due to
566 changes in the levels chromatin interactions at different alleles. Therefore, every
567 occurrence of a particular chromatin interaction would indicate the presence of one
568 cell, and the number of loops would be equivalent to the number of cells containing
569 the loop in HAP1 cells. As EZH2 KO HAP1 cells showed changing chromatin
570 interactions, we can infer that this is likely to be due to changing numbers of cells
571 that contain such chromatin interactions.

572 Taken together, these results demonstrated that H3K27me3 perturbation by
573 EZH2 inhibition, either genetically or pharmacologically, can lead to alteration of
574 long-range chromatin interactions.

575

576 **Integrative analysis of H3K27me3, H3K27ac and chromatin interactions upon** 577 **EZH2 inhibition**

578 Since several examples including 4C-seq using *FGF18* promoter as the bait
579 showed long-range chromatin interaction changes upon GSK343 treatment which is
580 consistent with previous MRR2-A1 KO results, we wondered if all the 4C libraries
581 showed the same trend. We classified the chromatin interactions into three
582 categories (short distance, intermediate distance and long distance) based on the
583 distance to bait and found four libraries show the same trend upon 5 μ M GSK343
584 treatment that short distance category has higher proportion of unchanged loops
585 (Figure 9A). A similar trend was also observed in 1 μ M GSK343-treated K562 cells
586 and HAP1 *EZH2* KO cells (Figure S8A). The results of all these libraries strengthen

587 the conclusion that long-range chromatin interactions are susceptible to EZH2
588 inhibition. It is interesting to note that although EZH2 inhibition and chromatin
589 interaction anchor knockout are two very different types of perturbation experiments,
590 both show that long-range chromatin interactions have a higher tendency to change
591 upon perturbation as compared with short-range chromatin interactions.

592 Next, we examined the constant and dynamic chromatin interactions in
593 relation to gene upregulation. We chose the MRR2-A1 region for our EZH2 inhibition
594 analyses in order to compare our results with the MRR2-A1 KO results. 4C-seq data
595 with MRR2-A1 as the bait showed 29 lost loops and 13 gained loops upon GSK343
596 treatment (Figure 9C). We found the loop to *IGF2* remained unchanged (Figure 9D-E,
597 Figure S8C) while *IGF2* expression was increased (Figure 5E). This phenomenon
598 also observed in MRR1-A1-*FGF18* loop (Figure S8B). We speculated that loss of
599 H3K27me3 at a silencer engaged in stable looping to a target gene promoter will
600 lead to loss of gene silencing at the gene promoter. Next, to investigate changing
601 chromatin interactions, we selected *TRPM5* gene as an example from 29 lost loops
602 (Figure 9C). *TRPM5* gene was significantly upregulated upon GSK343 treatment
603 (Figure 9F). This upregulation was accompanied by disrupted looping to MRR2-A1
604 which was confirmed by 3C-PCR (Figure 9D-F, Figure S8D). Notably, *TRPM5* gene
605 promoter is more distal than *IGF2* gene promoter in terms of the distance to MRR2-
606 A1 bait, which again supports the conclusion that long-range chromatin interactions
607 tend to change.

608 As the MRR2-A1 KO example demonstrated that initial histone state is
609 associated with chromatin interactions and silencer KO leads to altered chromatin
610 interactions and histone state which demonstrates interplay between histone
611 modifications and chromatin interactions (Figure 7E), we asked whether EZH2
612 inhibition by GSK343 will also lead to histone modifications alterations at changing
613 and unchanging chromatin interactions. We performed integrative analysis using
614 MRR2-A1 4C-seq and ChIP-seq as we did for the KO clones (Figure 10A-B). Unlike
615 integrative analysis of MRR2-A1 KO which showed that the initial histone state could
616 predict which chromatin interactions would change (Figure 6D), in the DMSO
617 condition, high H3K27ac levels and low H3K27me3 levels were not associated with
618 unchanged chromatin interactions (Figure S9A).

619 Upon GSK343 treatment, we observed there are global histone modification
620 changes which was shown as decreased H3K27me3 levels and increased H3K27ac
621 levels for all three categories (unchanged, gained and lost loops) (Figure 10A-B),
622 which is consistent with the western blot results (Figure S7A-B). In terms of the two
623 upregulated genes (*IGF2* and *TRPM5*) that we explored before, they both
624 demonstrated loss of H3K27me3 and gain of H3K27ac at the 4C interacting anchors
625 (Figure 10C) although the loop to *IGF2* remained unchanged while the loop to
626 *TRPM5* was reduced. This trend of decreased H3K27me3 and increased H3K27ac
627 was also observed in *FGF18* which showed stable looping with increased gene
628 expression upon GSK343 treatment (Figure S9B).

629 Taken together, the integrative analysis combined with the 3C-PCR showed
630 two models regarding how EZH2 inhibition leads to target gene upregulation (Figure
631 10D). Model 1 showed decreased H3K27me3 levels with stable loop upon GSK343
632 treatment which applies to both *IGF2* gene and *FGF18* gene. However, we noticed
633 differences between 4C-seq using the *IGF2* promoter as the bait and 4C-seq using
634 the *FGF18* promoter as the bait (Figure S9C-D). Specifically, there are many
635 repressive loops lost at the *IGF2* promoter while there are only a few repressive
636 loops lost at the *FGF18* promoter in GSK343 condition which may explain the

637 differences in gene upregulation upon GSK343 treatment (Figure 3E, Figure 5E).
638 Model 2 showed decreased H3K27me3 levels with disrupted loop upon GSK343
639 treatment as observed with the *TRPM5* gene (Figure 10D). Therefore, in terms of the
640 relationship between H3K27me3, chromatin interactions and gene upregulation, we
641 think that there are two different models. The first model is that long-range chromatin
642 interactions facilitate the deposition of H3K27me3 modification onto the target gene
643 promoter by MRRs to repress target genes (e.g. *IGF2* and *FGF18*). The second
644 model is that depletion of H3K27me3 abrogates long-range chromatin interactions,
645 which in turn cause upregulation of target genes (e.g. *TRPM5*).

646

647 Discussion

648 Silencers are important regulatory elements for gene regulation, and several
649 studies have suggested that they loop to target genes, in a manner analogous to
650 enhancers. Although there are several examples of proposed silencers that have
651 been experimentally validated (Table S1) and several methods have been proposed
652 to identify silencer elements (Table S2), however, there is however no consensus on
653 their foolproof identity yet. Additionally, except several PRC2-bound silencers in
654 mouse¹³ no silencers that work via a looping mechanism have been characterized
655 yet. Here, we propose a new method to identify H3K27me3-rich regions (MRRs) or
656 putative “super-silencers” through clustering and ranking H3K27me3 signals.

657 We found that MRRs are highly associated with chromatin interactions and
658 can be perturbed by EZH2 inhibition. Through H3K27me3 clustering, ranking and
659 associate them with chromatin interactions, we validated two looping silencer
660 examples (MRR1-A1 and MRR2-A1). We showed that silencer removal cause cell
661 identity changes and further related to tumor growth inhibition. Moreover, MRR2-A1
662 example demonstrated that silencer removal will cause changes of long-range
663 chromatin interactions and high H3K27ac loops were gained to activate *IGF2* gene
664 expression.

665 The mechanism of how silencers function to repress genes will be an
666 interesting topic to explore. Through the *IGF2* silencer example, we showed that that
667 looping silencer removal causes distant loops to change and histone states in the
668 initial conditions can predict loop changes. Importantly, we found that loops with high
669 H3K27ac and low H3K27me3 tend to change, which provides evidence that histone
670 modifications can affect overall genome architecture. Secondly, we found that short-
671 range loops tend to remain unchanged while long range loops are disturbed either
672 upon silencer KO or GSK343 treatment which is in line with the finding that showed
673 PRC1 and PRC2 are necessary to maintain the chromatin interactions landscape^{17,61}.
674 Thirdly, there are multiple regions inside an MRR that are involved in chromatin
675 interactions and may also function as silencers. It would be interesting to see
676 whether the putative silencers in an MRR function similarly or differently and to
677 dissect different functional mechanisms of silencers. Fourthly, transcription factors
678 can contribute to the chromatin interaction landscape and cell type-specific
679 transcription factors may result in different chromatin interaction landscape⁶².
680 Therefore, elucidating the transcription factors involved in silencer functioning would
681 be an important future direction for research.

682 Another interesting question would be the importance of H3K27me3 at MRR
683 and H3K27me3 on target gene promoters. In our CRISPR knockout results, we
684 observed that excision of a distally interacting MRR region (MRR2-A1) to *IGF2* can
685 lead to *IGF2* upregulation, which indicated the repressive ability of H3K27me3 at
686 distal MRR. Notably, the residual H3K27me3 on the *IGF2* gene promoter (Figure 5C)

687 still showed a repressive effect even after excision of MRR2-A1. However, we still
688 cannot infer the relative importance of H3K27me3 at MRR and H3K27me3 on target
689 gene promoters. We also cannot exclude the possibility that there are other distal
690 silencers controlling gene expression. This question could be further addressed by
691 more targeted perturbation of H3K27me3 at both or either end of the chromatin
692 interactions.

693 Our pharmacological and genetic inhibition of EZH2 showed that MRR-
694 associated genes as well as long-range chromatin interactions were susceptible to
695 the depletion of H3K27me3 histone marks. MRR-associated genes were more
696 susceptible to the depletion of H3K27me3 marks than genes associated with typical
697 H3K27me3 peaks. This result suggested that the response of different genes to
698 H3K27me3 loss may correlate with their chromatin state. Although differences in
699 chromatin interactions have been observed in cells at different developmental
700 stages^{58,59}, whether chromatin interactions can be affected by histone modifications
701 and such perturbations is still an open question. A study in human fibroblast cells
702 showed that the contacts between enhancers and promoters were present in the
703 cells before the transient treatment of TNF- α ⁶⁰, suggesting a pre-existing and stable
704 chromatin architecture. However, we observed that long-range chromatin
705 interactions are susceptible to EZH2 inhibition or knockout, which is consistent with
706 previous studies showing that PRC1^{18,63} and PRC2 complexes⁶³ are necessary for
707 long-range chromatin interactions formation. Our results are different from these
708 previous studies in that we dived into more details by classifying the loops into
709 different categories and performing plenty of different 4C libraries in both GSK343
710 condition and KO condition. Furthermore, through 4C and ChIP-seq integrative
711 analysis, we revealed the interplay between histone modifications and changing
712 chromatin interactions. Taken together, our results suggest that regulatory elements
713 at a great distance can be brought into proximity to genes and form a permissive or
714 repressive microenvironment around genes to help regulate their expression. To
715 address the relationship of histone modifications and chromatin interaction formation,
716 further investigation of the structural differences in response to different cell
717 treatments should be done using high-resolution and whole-genome chromatin
718 interactions sequencing methods. This can help us to understand the mechanisms of
719 gene activation or repression in cellular pathways.

720 We and other people found that silencers are cell-type specific and highly
721 context-dependent²⁷⁻²⁹ (Table S2). Specifically, the same genomic region was a
722 silencer in one cell line but a super-enhancer in another cell line. Not surprisingly,
723 this change is associated with different gene expression in the different cell lines.
724 Moreover, it has been shown that silencers can transit into active enhancers during
725 differentiation¹³. Thus, the study of relationships between cell types and silencers
726 can shed light on cell type specific regulation of gene expression. The mechanism by
727 which important oncogenes such as *TERT* are silenced in normal cells is unclear. It
728 would be interesting to investigate whether *TERT* is regulated by MRRs that transit
729 into active enhancers in cancer cells.

730 Interestingly, we found that silencer removal leads to cell differentiation and
731 tumor growth inhibition, which is in line with previous observed studies that showed
732 that more H3K27me3 can render Topologically-Associated Domains (TADs) inactive
733 and repress tumor suppressor genes⁶¹. It will be interesting to study the detailed
734 mechanism of how silencers regulate tumor suppressor genes. In this way, it may be
735 possible for us to activate the tumor suppressor genes expression by perturbing

736 silencers, just as super-enhancer perturbation can result in loss of oncogene
737 expression³².

738 Notably, the question of whether super-enhancers are indeed different from
739 enhancers is not settled yet⁶⁴. Our research raises similar questions: are MRRs,
740 which are potentially “super-silencers”, different from typical silencers? The regions
741 of the long MRR that are critical for silencer function are not fully elucidated yet. Here
742 we showed that the components of the MRRs that are involved in looping
743 interactions are important in repressing long-range chromatin interactions, while the
744 roles of other components of the MRRs are not yet known. Moreover, we found that
745 different anchors within the same MRR can be associated with different proteins,
746 suggesting that these different anchors may play different roles within the MRR.
747 Detailed dissection of the different anchors and other components of MRRs will be
748 required to answer these questions in future work.


749 Moreover, it will be interesting to explore how looping is mediated at MRRs.
750 Given that super-enhancers have been shown to be involved in phase
751 condensation⁶⁵, and HP1 which is a component of constitutive heterochromatin
752 associated with H3K9me3 has also been shown to be able to form phase
753 condensates⁶⁶, it would be interesting to explore whether PRC2 complex and
754 H3K27me3 can give rise to phase condensates.

755 In conclusion, maintenance of cellular identity requires that the right genes are
756 expressed and other genes are silenced. Distal looping silencers have been well
757 explored in *Drosophila* and mice⁶⁷ but there are no known examples in human. Our
758 results add to the understanding of silencers by identifying silencer elements in
759 human and demonstrating the existence of looping silencers in human. Just as the
760 concept of “super-enhancers” has been useful in identifying oncogenes and
761 therapeutic vulnerabilities in cancer cells, the concept of silencers calling by
762 clustering of H3K27me3 may be useful in identifying genes involved in controlling
763 cellular identity and cancer progression.

764

765 **Methods**

766 We performed Hi-C interaction analysis, ChIP-seq, RNA-seq, gene expression
767 analyses, cell culture, RT-qPCR, CRISPR excision, 4C, 3C, xenograft models,
768 western blot, adhesion assays, and growth curves as described in the
769 **Supplementary Methods**. A list of all libraries used and generated is provided in
770 **Supplementary Table S3**. A list of all the primers used is provided in
771 **Supplementary Table S4**.



772
 773
 774
 775
 776

777 **Figure 1. Definition of H3K27me3-rich regions (MRRs) and their**
778 **characterization.**

779 **A.** H3K27me3 ChIP-seq peaks within 4kb are stitched together and the stitched
780 peaks ranked according to their H3K27me3 signal. The rank-ordered signal with a
781 slope of 1 is used as cut-off for defining H3K27me3-rich MRRs. Constituent peaks,
782 peaks that are stitched during the process of merging peak. **B.** H3K27me3-rich
783 regions (MRRs) and typical H3K27me3 peaks in K562 and their associated genes. A
784 representative overlapping gene from each of the top 10 MRRs was shown. **C.**
785 Overlap of MRR and typical H3K27me3 with ReSE list²⁹. The Venn diagram shows
786 the observed overlap between our MRR (H3K27me3-rich region)/typical H3K27me3
787 peaks and the ReSE list. Left barplot: The barplots show the percentage of the
788 overlap number relative to total number in ReSE list. Actual, observed overlap
789 percentage; expected, expected overlap percentage generated by: 1) first randomly
790 shuffled 1000 times on MRR/typical H3K27me3 peaks on the same chromosome; 2)
791 calculated overlap percentage using the 1000 time randomly shuffled regions.
792 Wilcoxon test p values are indicated, ns: $p > 0.05$, *: $p \leq 0.05$, **: $p \leq 0.01$, ***: p
793 ≤ 0.001 , ****: $p \leq 0.0001$. Right barplot: The difference between actual and
794 expected percentage. Difference in percentage is calculated by actual percentage
795 minus expected percentage. **D.** ChIP-seq signal on typical H3K27me3, MRR,
796 constituent peaks of typical H3K27me3 peaks, and constituent peaks of MRR
797 regions in K562. Peaks are scaled to the same median length of peaks in typical
798 H3K27me3 (1070 bp), MRR (92170 bp), constituent peaks of typical H3K27me3
799 (221 bp), or constituent peaks of MRRs (199 bp), and the plot expanded by 5kb on
800 both sides of the peak. **E.** Expression changes associated with different peaks
801 between different cells. K562 vs. GM12878/K562 vs. HAP1 cell lines used in the
802 comparison. Genes are classified based on the states of their overlapping peaks in
803 different cell lines: [state in the first cell line] vs. [state in the second cell line], where
804 the state can be super-enhancer (SE), H3K27me3-rich region (MRR), typical
805 enhancer (H3K27ac), typical H3K27me3 peak (H3K27me3), or no overlapping peaks
806 (Others). The expression data is from Epigenetic RoadMap⁶⁸ and in-house HAP1
807 RNA-seq. Wilcoxon test p values are as indicated. **F.** Constituent peaks of MRRs
808 have more Hi-C interactions compared to the constituent peaks of typical H3K27me3.
809 Constituent peaks are peaks that form MRRs as described in A. The shuffled peaks
810 are generated by expanding the midpoint of each constituent peaks to the median
811 length of all the constituent peaks, and then followed by random genomic region
812 shuffling. Wilcoxon test p values are indicated, ns: $p > 0.05$, *: $p \leq 0.05$, **: $p \leq$
813 0.01 , ***: $p \leq 0.001$, ****: $p \leq 0.0001$.

814

815

816

817

818

819

820

821

822


823

824

825

826

827



828

829


830

831

832 **Figure 2. H3K27me3-rich regions (MRRs) preferentially associate with MRRs in**
833 **the human genome via chromatin interactions.**

834 **A.** Schematic plot of how different categories of Hi-C interactions are defined. Hi-C
835 anchors are classified by whether they overlap with H3K27me3 or H3K27ac peaks.
836 A (active), overlap with only H3K27ac peaks; R (repressive), overlap with only
837 H3K27me3 peaks; Q (quiescent), overlap with neither H3K27ac nor H3K27me3
838 peaks; B (both), overlap with both H3K27ac and H3K27me3 peaks. The height of Hi-
839 C interactions (arcs) represents the highest read counts in the interacting regions. **B.**
840 Observed/expected ratio of Hi-C interactions in different categories. Left: categories
841 of chromatin pair states. Right: T (typical H3K27me3) or H (MRR) peaks. The
842 expected interactions are calculated from the marginal distributions of different
843 anchors. **C.** Different categories of MRR associated with genes. **D.** H3K27me3-rich
844 regions (MRRs) and typical H3K27me3 peaks in K562 and their associated genes
845 through chromatin interactions. Peaks overlapping with Hi-C interactions are labeled
846 with associated genes: for peaks labeled “proximal”, the gene TSS and peak occupy
847 the same Hi-C anchor; “distal” peaks are connected to the gene via Hi-C interactions.
848 **E.** Expression of genes that are associated with MRR in proximal, distal, and internal
849 category in K562 cells. The three categories are described in **C**. The control category
850 is generated by: 1) first filtering out genes that are overlapped with ENCODE
851 blacklist regions and also H3K9me3 peaks as H3K9me3 is associated with
852 constitutive heterochromatin and such regions are likely to be highly silenced; 2) only
853 retaining genes that overlapped with Hi-C interactions; 3) randomly sampling the
854 same amount of genes as the average gene number in proximal/distal/internal
855 category. Wilcoxon test p values are indicated, ns: $p > 0.05$, *: $p \leq 0.05$, **: $p \leq$
856 0.01 , ***: $p \leq 0.001$, ****: $p \leq 0.0001$. **F.** Example of 4C at the *TMCO4* gene
857 promoter bait showing extensive internal looping within an MRR in K562. The colors
858 of 4C interactions are based on the distal interacting regions to the 4C bait. Blue:
859 repressive; orange: active; green: both; grey: quiescent. The state of the 4C bait is
860 labeled by text. Each ChIP-seq tracks contains ChIP signal and peaks. TE, typical
861 enhancer; SE, super-enhancer; T, typical H3K27me3; MRR, H3K27me3-rich region.
862 **G.** Heatmap of transcription factors binding enrichment at interacting regions of
863 MRRs. Each row representing an interacting region of MRRs. The number
864 overlapping transcription factor peaks at interacting regions are normalized to Z
865 score per transcription factor. Red colors indicate more binding events.

866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881




882
883
884
885

886 **Figure 3. CRISPR excision of MRR1-A1 leads to gene upregulation of multiple**
887 **proximal and looping genes including *FGF18*.**

888 **A.** Screenshot showing EZH2 ChIP-seq, H3K27me3 ChIP-seq, H3K27ac ChIP-seq
889 and chromatin interactions as identified from previously published Hi-C data²², gene
890 information, and 4C performed on the CRISPR-excised region in wild-type cells
891 confirming chromatin interactions to *FGF18*, as well as showing chromatin
892 interactions to *UBTD2* and other genes. The regions highlighted in the red boxes are
893 shown in more detail, with RNA-seq was shown as one CRISPR knockout clone over
894 wild-type at *FGF18* and *UBTD2*. The blue bar shows the predicted whole MRR. The
895 red box with the red scissors indicates the region which was excised. **B.** RNA-seq
896 fold changes calculated from two replicates of RNA-Seq data of MRR1-A1 looping
897 genes in one MRR1-A1 knockout clone (KO) as compared with one vector control
898 clone (“Empty Vector”; “EV”). **C.** RNA-seq fold changes of MRR1-A1 proximal genes
899 in KO as compared with EV. **D.** RT-qPCR of *FGF18*, *UBTD2* and *FBXW11* in three
900 different CRISPR-excised clones (“KO-1”, “KO-2”, “KO-3”) as compared with EV. **E.**
901 RT-qPCR of *FGF18* expression upon GSK343 treatment in EV and three KO clones.
902 Fold change was plotted compared to *GAPDH* for EV and KO cells in DMSO and
903 GSK343 condition. **F.** Gene Ontology (GO) was performed using significant
904 differentially expressed (DE) genes in the RNA-seq data which was shown as –
905 $\log_2(p \text{ value})$. All data shown here indicates average + standard error. P value less
906 than 0.05 is shown as *. P value less than 0.01 is shown as **.

907
908
909
910
911
912
913




914
915
916
917
918
919

920 **Figure 4. CRISPR excision of MRR1-A1 leads to altered adhesion, erythroid**
921 **differentiation and tumor growth inhibition.**

922 **A.** Light microscopy photos of empty vector (EV) and CRISPR knockout clones (KO)
923 showing increased cell adhesion and aggregates in the KO clones. 10X and 20X
924 magnification were shown. **B.** A fibronectin adhesion assay showed increased
925 adhesion of the three CRISPR knockout clones (KO) as compared with empty vector
926 (EV). Bovine Serum Albumin (BSA) was used as a negative control. **C.** RT-qPCR of
927 haemoglobin genes (*HBB*, *HBZ* and *HBE1*) in EV and two KO clones. **D&E.** Tumor
928 growth in SCID (Severe Combined Immunodeficiency) mice injected with MRR1-A1
929 knock out clones and empty vector cells (EV). The upper panel shows the tumor
930 growth curve, and data shown as tumor volume with different post implantation days.
931 The panel below was the representative tumor picture at the final day. **F.** Model of
932 MRR1-A1 excision leads to multiple genes change which further leads to cell
933 adhesion, differentiation and tumor growth inhibition. All data shown here indicates
934 average + standard error. P value less than 0.05 is shown as *. P value less than
935 0.01 is shown as **.

936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959




960

961

962


963

964 **Figure 5. CRISPR excision of MRR2-A1 leads to multiple gene upregulation**
965 **including *IGF2* gene, erythroid differentiation and tumor growth inhibition.**
966 **A.** Screenshot showing EZH2 ChIP-seq, H3K27me3 ChIP-seq, H3K27ac ChIP-seq
967 and chromatin interactions as identified from previously published Hi-C data²², gene
968 information, and 4C performed on the CRISPR-excised region in wild-type cells
969 confirming chromatin interactions to *IGF2* as well as other genes. The blue bar
970 shows the predicted MRR. The red box with the red scissors indicates the region
971 which was excised. **B.** RNA-seq fold changes of MRR2-A1 looping genes in KO as
972 compared with EV. **C.** RNA-seq fold changes of MRR2-A1 proximal genes in KO as
973 compared with EV. **D.** RT-qPCR of *IGF2* in three different CRISPR-excised clones
974 (KO-1, KO-2, KO-3) as compared with vector control cells (“EV”). **E.** RT-qPCR of
975 *IGF2* expression upon GSK343 treatment in EV and three KO clones. Fold change
976 was plotted compared to *GAPDH* for EV and KO cells in DMSO and GSK343
977 condition. **F.** Gene Ontology (GO) was performed using significant DE genes in the
978 RNA-seq data shown as $-\log_2(p \text{ value})$. **G.** RT-qPCR of haemoglobin genes (*HBB*,
979 *HBZ* and *HBE1*) in EV and two KO clones. **H.** Tumor growth in SCID (Severe
980 Combined Immunodeficiency) mice injected with MRR2-A1 knock out cells and
981 empty vector cells (EV). The upper panel shows the tumor growth curve, and data
982 shown as tumor volume with different post implantation days. The panel below was
983 representative tumor picture at the final day. All data shown here indicates average +
984 standard error. P value less than 0.05 is shown as *. P value less than 0.01 is shown
985 as **. P value less than 0.001 is shown as ***.
986
987



988
989
990
991
992


993 **Figure 6. Initial histone states predict the changed loops upon MRR2-A1**
994 **removal.**
995 **A.** Representative chromatin interactions at *IGF2* bait in KO and control clones which
996 shown as loops. **B.** The average distance of changed loops (gained loops and lost
997 loops) is greater than unchanged loops upon MRR2-A1 KO when using *IGF2*
998 promoter as the bait. **C.** ChIP-seq and ChIP-qPCR of H3K27me3 and H3K27ac for
999 four regions (R1-R4) at *IGF2* gene in EV and KO clones. Data shown here are
1000 average + standard error. P value less than 0.05 is shown as *. P value less than
1001 0.01 is shown as **. **D.** Heatmap about Integrative analysis of 4C, H3K27me3 and
1002 H3K27ac ChIP-seq in EV. Left panel: different 4C regions are classified according to
1003 their H3K27me3 signal intensity in EV. H3K27me3 signal level at these 4C regions
1004 are tertiled in three cohorts: high, medium, and low. 4C region type indicates
1005 different categories of 4C regions (Gained, lost and unchanged). The 4C interaction
1006 intensities are shown in log₁₀ (RPM). Right panel: different 4C regions are classified
1007 according to their H3K27ac signal intensity in EV. Similar to the left panel, the
1008 H3K27ac signal level at these 4C regions are tertiled in three cohorts.



1010 **Figure 7. Unchanged loops and gained loops to *IGF2* become increased**
1011 **H3K27ac and decreased H3K27me3 levels upon MRR2-A1 removal.**

1012 **A.** Heatmap of ChIP-seq signal changes of H3K27me3 and H3K27ac at different
1013 types of 4C regions (gained, lost and unchanged) in empty vector (EV) and MRR2-
1014 A1 KO clones. Blue arrow: this region is shown as a screenshot in panel C. Red
1015 arrow: this region is shown as a screenshot in panel D. **B.** Boxplots of ChIP-seq
1016 signal changes of H3K27me3 and H3K27ac at different types of 4C regions in EV
1017 and MRR2-A1 KO clones. The same 4C regions are connected by grey lines.
1018 Wilcoxon paired test p value are indicated. **C.** Zoomed screenshot about one of the
1019 unchanged 4C regions indicated in **A** which showed decrease of H3K27me3. **D.**
1020 Zoomed screenshot about one of the gained 4C regions in **A** which showed increase
1021 of H3K27ac. **E.** 3-dimensional and 2-dimensional cartoon schematics of our
1022 proposed model that initial histone states are associated with changed loops and
1023 MRR2-A1 removal leads to increase of H3K27ac levels on unchanged loops and
1024 gain of chromatin loops in regions with high H3K27ac levels.

1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059




1060
1061
1062
1063
1064

1065 **Figure 8. MRR-associated gene expression and chromatin interactions**
1066 **changes after EZH2 perturbation.**

1067 **A.** H3K27me3 ChIP-seq signal at peaks from DMSO-treated and 5 μ M GSK343-
1068 treated K562 cells. The H3K27me3 ChIP-seq peaks are called using MACS2 in
1069 DMSO and GSK343 condition respectively, and then ChIP-seq signal are calculated
1070 on these two sets of peaks. The top panel shows the average H3K27me3 signal of
1071 H3K27me3 peaks in DMSO and GSK343 condition. The middle panel shows the
1072 changes of H3K27me3 signal at the DMSO H3K27me3 peaks. The bottom panel
1073 shows the changes of H3K27me3 signal at the GSK343 H3K27me3 peaks. The
1074 remaining H3K27me3 peaks in GSK343 condition have higher H3K27me3 levels in
1075 DMSO condition. **B.** Expression changes of genes associated with different types of
1076 peaks in 5 μ M GSK343-treated K562 cells. Genes included: 1) Genes with
1077 transcription start sites (TSS) overlapped with different peaks; 2) Genes associated
1078 with different peaks through Hi-C interaction. One-tail wald test was used for testing
1079 significantly up-regulation. All the P values of genes in each category are aggregated.
1080 Wilcoxon test p values are indicated, ns: $p > 0.05$, *: $p \leq 0.05$, **: $p \leq 0.01$, ***: p
1081 ≤ 0.001 , ****: $p \leq 0.0001$. **C.** 4C results of *FGF18* in DMSO and GSK343-treated
1082 K562 cells. The colors of 4C interactions are based on the distal interacting regions
1083 to the 4C bait. Blue: repressive; orange: active; green: both; grey: quiescent. The
1084 height of the 4C is shown in Reads Per Million (RPM). The ChIP-seq signal and
1085 peaks of H3K27ac, H3K27me3, and H3K4me3 are shown. **D.** Zoomed-in view of
1086 1000kb region downstream of the 4C bait indicated in **C**. Top and bottom panel, 4C
1087 interactions in DMSO and 5 μ M GSK343 conditions. Noted that the y-axis is in
1088 distance to the 4C bait. The colors of the 4C interactions are the same as in **C**.
1089 Middle panel, detail types of the 4C HindIII fragment. Grey, unchanged 4C regions,
1090 which are the 4C interactions that are present in both DMSO and 5 μ M GSK343
1091 conditions; Red, gained 4C regions, which are the 4C interactions that are only
1092 present in 5 μ M GSK343 condition; Green, lost 4C regions, which are the 4C
1093 interactions that are only present in DMSO condition. All the 4C regions are shown in
1094 two alternate rows to have a better visual separation. **E.** Zoomed-in view of 50kb
1095 region downstream of the 4C bait indicated in **C**. The details of each panel are the
1096 same as in **D**. **F.** Density plot of different categories of 4C interactions on the same
1097 chromosome as the bait. All the 4C interactions that have p-value < 0.05 on the
1098 same chromosome as the 4C bait are included. Gained, 4C interactions present in
1099 GSK343-treated 4C but not DMSO-treated 4C; lost, 4C interaction present in DMSO-
1100 treated 4C but not GSK343-treated 4C; unchanged, 4C interactions present in both
1101 DMSO-treated and GSK343-treated 4C. Mean distances of each category are
1102 indicated by the vertical dashed line.


1103
1104
1105
1106



1107
1108
1109
1110

1111 **Figure 9. Analysis of stable and changing chromatin interactions upon EZH2**
1112 **inhibition.**

1113 **A.** Proportion of unchanged 4C interactions in different distance categories (short,
1114 intermediate and long) in 5 μ M GSK343-treated K562 cells. The bait name is used as
1115 the name of the 4C libraries. As the distance of 4C interactions increases, the
1116 proportion of unchanged 4C interactions drops, suggesting that long-range
1117 interactions are perturbed. **B.** The average distance of changed loops (gained loops
1118 and lost loops) is greater than unchanged loops upon GSK343 treatment when using
1119 MRR2-A1 as the bait. **C.** Venn diagram of 4C chromatin interactions using MRR2-A1
1120 as the bait in DMSO and GSK343 condition. **D.** Table of Reads Per Million (RPMs) of
1121 4C chromatin interactions in two individual replicates. **E.** 3C-PCR of *IGF2*-MRR2-A1
1122 loop in DMSO and GSK343 condition. The data is shown as relative intensity. **F.** RT-
1123 qPCR of *TRPM5* gene and 3C-PCR of *TRPM5*-MRR2-A1 in DMSO and GSK343
1124 condition. All data shown here are average + standard error. P value less than 0.01
1125 is shown as **.



1126
1127
1128
1129
1130

1131 **Figure 10. Integrative analysis of H3K27me3, H3K27ac and chromatin**
1132 **interactions upon EZH2 inhibition.**
1133 **A.** Heatmap of ChIP-seq signal changes of H3K27me3 and H3K27ac at different
1134 types of 4C regions (gained, lost and unchanged) in DMSO and GSK343 treated
1135 K562 cells. **B.** Boxplots of ChIP-seq signal changes of H3K27me3 and H3K27ac at
1136 different types of 4C regions in DMSO and GSK343 treated K562 cells. The same
1137 4C regions are connected by grey lines. Wilcoxon paired test p value are indicated.
1138 **C.** Screenshot of H3K27me3 and H3K27ac ChIP-seq at MRR2-A1, *IGF2* gene and
1139 *TRPM5* gene regions in DMSO and GSK343 as well as 4C-seq using MRR2-A1 as
1140 the bait. MRR2-A1 bait, *IGF2* bait and *TRPM5* bait were highlighted and zoomed in
1141 for ChIP-seq. **D.** 3-dimensional and 2-dimensional cartoon schematics of our
1142 proposed model involving two mechanisms of how GSK343 leads to *IGF2* gene and
1143 *TRPM5* gene upregulation at stable and changing chromatin interactions
1144 respectively.
1145

1146 **Acknowledgements**

1147 We would like to thank all members of the Fullwood Lab and Ah Jung Jeon for
1148 helpful comments. This research is supported by the National Research Foundation
1149 (NRF) Singapore through an NRF Fellowship awarded to M.J.F (NRF-NRFF2012-
1150 054) and NTU start-up funds awarded to M.J.F. This research is supported by the
1151 RNA Biology Center at the Cancer Science Institute of Singapore, NUS, as part of
1152 funding under the Singapore Ministry of Education Academic Research Fund Tier 3
1153 awarded to Daniel Tenen as lead PI with M.J.F as co-investigator (MOE2014-T3-1-
1154 006). This research is supported by a Singapore MOE Academic Research
1155 Research Fund (T1) grant to G.T-K. This research is supported by an National
1156 Research Foundation Competitive Research Programme grant awarded to V.T. as
1157 lead PI and M.J.F. as co-PI (NRF-CRP17-2017-02). This research is supported by the
1158 National Research Foundation Singapore and the Singapore Ministry of Education
1159 under its Research Centres of Excellence initiative.

1160

1161 **Author contributions**

1162 Y.C.C., Y.Z., M.J.F. and G.T-K. conceived of the research. Y.C.C., Y.Z., M.J.F. and
1163 G.T-K. contributed to the study design. Y.C.C. performed bioinformatics analysis.
1164 Y.Z. and S.L. designed CRISPR knock out experiments. Y.Z. performed CRISPR
1165 knock out, 4C, 3C-PCR, RNA-seq, ChIP-seq, ChIP-qPCR and other functional
1166 experiments for KO clones. Y.Z. and Y.P.L. performed EZH2 inhibitor and HAP1
1167 *EZH2* knockout experiments and 4C experiments. E.L-A. advised on the
1168 interpretation of EZH2 inhibitor results. J.Q.T performed ChIP-seq and ChIP-qPCR
1169 experiments for HAP1 *EZH2* KO cells. Z.C. and M.Q.L. performed 4C experiments.
1170 A.R., L.M. and V.T. designed xenograft experiments. A.R. performed xenograft
1171 experiments. Y.C.C., Y.Z., M.J.F. and G.T-K. reviewed the data and wrote the
1172 manuscript. All authors reviewed and approved of the manuscript.

1173

1174 **Data deposition**

1175 The list of libraries used in the study is provided in Table S3. All datasets have been
1176 deposited into GEO.

1177

1178 **Author information**

1179 The authors declare that they have no competing interests.
1180 Correspondence and requests for materials should be addressed to
1181 mfullwood@ntu.edu.sg and dbsgtk@nus.edu.sg.

1182

1183

1184

1185

1186

1187

1188

1189

1190

1191

1192

1193

1194

1195

1196 References

- 1197 1 Schmitt, A. D., Hu, M. & Ren, B. Genome-wide mapping and analysis of
1198 chromosome architecture. *Nat Rev Mol Cell Biol* **17**, 743-755,
1199 doi:10.1038/nrm.2016.104 (2016).
- 1200 2 See, Y. X., Wang, B. Z. & Fullwood, M. J. Chromatin Interactions and
1201 Regulatory Elements in Cancer: From Bench to Bedside. *Trends Genet* **35**,
1202 145-158, doi:10.1016/j.tig.2018.11.007 (2019).
- 1203 3 Babu, D. & Fullwood, M. J. 3D genome organization in health and disease:
1204 emerging opportunities in cancer translational medicine. *Nucleus* **6**, 382-393,
1205 doi:10.1080/19491034.2015.1106676 (2015).
- 1206 4 Bradner, J. E., Hnisz, D. & Young, R. A. Transcriptional Addiction in Cancer.
1207 *Cell* **168**, 629-643, doi:10.1016/j.cell.2016.12.013 (2017).
- 1208 5 Akincilar, S. C. *et al.* Long-Range Chromatin Interactions Drive Mutant TERT
1209 Promoter Activation. *Cancer Discov* **6**, 1276-1291, doi:10.1158/2159-
1210 8290.CD-16-0177 (2016).
- 1211 6 Li, L., Suzuki, T., Mori, N. & Greengard, P. Identification of a functional
1212 silencer element involved in neuron-specific expression of the synapsin I gene.
1213 *Proc Natl Acad Sci U S A* **90**, 1460-1464 (1993).
- 1214 7 Zuccato, C. *et al.* Widespread disruption of repressor element-1 silencing
1215 transcription factor/neuron-restrictive silencer factor occupancy at its target
1216 genes in Huntington's disease. *J Neurosci* **27**, 6972-6983,
1217 doi:10.1523/JNEUROSCI.4278-06.2007 (2007).
- 1218 8 Donda, A., Schulz, M., Burki, K., De Libero, G. & Uematsu, Y. Identification
1219 and characterization of a human CD4 silencer. *Eur J Immunol* **26**, 493-500,
1220 doi:10.1002/eji.1830260232 (1996).
- 1221 9 Sawada, S., Scarborough, J. D., Killeen, N. & Littman, D. R. A lineage-specific
1222 transcriptional silencer regulates CD4 gene expression during T lymphocyte
1223 development. *Cell* **77**, 917-929, doi:10.1016/0092-8674(94)90140-6 (1994).
- 1224 10 Kolovos, P., Knoch, T. A., Grosveld, F. G., Cook, P. R. & Papantonis, A.
1225 Enhancers and silencers: an integrated and simple model for their function.
1226 *Epigenetics Chromatin* **5**, 1, doi:10.1186/1756-8935-5-1 (2012).
- 1227 11 Mifsud, B. *et al.* Mapping long-range promoter contacts in human cells with
1228 high-resolution capture Hi-C. *Nat Genet* **47**, 598-606, doi:10.1038/ng.3286
1229 (2015).
- 1230 12 Eagen, K. P., Aiden, E. L. & Kornberg, R. D. Polycomb-mediated chromatin
1231 loops revealed by a subkilobase-resolution chromatin interaction map. *Proc*
1232 *Natl Acad Sci U S A* **114**, 8764-8769, doi:10.1073/pnas.1701291114 (2017).
- 1233 13 Ngan, C. Y. *et al.* Chromatin interaction analyses elucidate the roles of PRC2-
1234 bound silencers in mouse development. *Nat Genet* **52**, 264-272,
1235 doi:10.1038/s41588-020-0581-x (2020).
- 1236 14 Muller, J. Transcriptional silencing by the Polycomb protein in Drosophila
1237 embryos. *EMBO J* **14**, 1209-1220 (1995).
- 1238 15 Margueron, R. & Reinberg, D. The Polycomb complex PRC2 and its mark in
1239 life. *Nature* **469**, 343-349, doi:10.1038/nature09784 (2011).
- 1240 16 Schuettengruber, B. & Cavalli, G. Polycomb domain formation depends on
1241 short and long distance regulatory cues. *PLoS One* **8**, e56531,
1242 doi:10.1371/journal.pone.0056531 (2013).
- 1243 17 Schoenfelder, S. *et al.* Polycomb repressive complex PRC1 spatially
1244 constrains the mouse embryonic stem cell genome. *Nat Genet* **47**, 1179-1186,
1245 doi:10.1038/ng.3393 (2015).

- 1246 18 Kundu, S. *et al.* Polycomb Repressive Complex 1 Generates Discrete
1247 Compacted Domains that Change during Differentiation. *Mol Cell* **65**, 432-446
1248 e435, doi:10.1016/j.molcel.2017.01.009 (2017).
- 1249 19 Schuettengruber, B. & Cavalli, G. Recruitment of polycomb group complexes
1250 and their role in the dynamic regulation of cell fate choice. *Development* **136**,
1251 3531-3542, doi:10.1242/dev.033902 (2009).
- 1252 20 Nakagawa, M. & Kitabayashi, I. Oncogenic roles of enhancer of zeste
1253 homolog 1/2 in hematological malignancies. *Cancer Sci* **109**, 2342-2348,
1254 doi:10.1111/cas.13655 (2018).
- 1255 21 Soufi, A., Donahue, G. & Zaret, K. S. Facilitators and impediments of the
1256 pluripotency reprogramming factors' initial engagement with the genome. *Cell*
1257 **151**, 994-1004, doi:10.1016/j.cell.2012.09.045 (2012).
- 1258 22 Bernstein, B. E. *et al.* A bivalent chromatin structure marks key developmental
1259 genes in embryonic stem cells. *Cell* **125**, 315-326,
1260 doi:10.1016/j.cell.2006.02.041 (2006).
- 1261 23 Hosogane, M., Funayama, R., Shiota, M. & Nakayama, K. Lack of
1262 Transcription Triggers H3K27me3 Accumulation in the Gene Body. *Cell Rep*
1263 **16**, 696-706, doi:10.1016/j.celrep.2016.06.034 (2016).
- 1264 24 Lee, T. I. *et al.* Control of developmental regulators by Polycomb in human
1265 embryonic stem cells. *Cell* **125**, 301-313, doi:10.1016/j.cell.2006.02.043
1266 (2006).
- 1267 25 Pauler, F. M. *et al.* H3K27me3 forms BLOCs over silent genes and intergenic
1268 regions and specifies a histone banding pattern on a mouse autosomal
1269 chromosome. *Genome Res* **19**, 221-233, doi:10.1101/gr.080861.108 (2009).
- 1270 26 Orlando, D. A., Guenther, M. G., Frampton, G. M. & Young, R. A. CpG island
1271 structure and trithorax/polycomb chromatin domains in human cells.
1272 *Genomics* **100**, 320-326, doi:10.1016/j.ygeno.2012.07.006 (2012).
- 1273 27 Huang, D., Petrykowska, H. M., Miller, B. F., Elnitski, L. & Ovcharenko, I.
1274 Identification of human silencers by correlating cross-tissue epigenetic profiles
1275 and gene expression. *Genome Res* **29**, 657-667, doi:10.1101/gr.247007.118
1276 (2019).
- 1277 28 Doni Jayavelu, N., Jajodia, A., Mishra, A. & Hawkins, R. D. Candidate silencer
1278 elements for the human and mouse genomes. *Nat Commun* **11**, 1061,
1279 doi:10.1038/s41467-020-14853-5 (2020).
- 1280 29 Pang, B. & Snyder, M. P. Systematic identification of silencers in human cells.
1281 *Nat Genet* **52**, 254-263, doi:10.1038/s41588-020-0578-5 (2020).
- 1282 30 Hnisz, D. *et al.* Super-enhancers in the control of cell identity and disease.
1283 *Cell* **155**, 934-947, doi:10.1016/j.cell.2013.09.053 (2013).
- 1284 31 Wang, X., Cairns, M. J. & Yan, J. Super-enhancers in transcriptional
1285 regulation and genome organization. *Nucleic Acids Res* **47**, 11481-11496,
1286 doi:10.1093/nar/gkz1038 (2019).
- 1287 32 Loven, J. *et al.* Selective inhibition of tumor oncogenes by disruption of super-
1288 enhancers. *Cell* **153**, 320-334, doi:10.1016/j.cell.2013.03.036 (2013).
- 1289 33 Hnisz, D. *et al.* Super-enhancers in the control of cell identity and disease.
1290 *Cell* **155**, 934-947, doi:10.1016/j.cell.2013.09.053 (2013).
- 1291 34 Pott, S. & Lieb, J. D. What are super-enhancers? *Nat Genet* **47**, 8-12,
1292 doi:10.1038/ng.3167 (2015).
- 1293 35 Consortium, E. P. An integrated encyclopedia of DNA elements in the human
1294 genome. *Nature* **489**, 57-74, doi:10.1038/nature11247 (2012).

- 1295 36 Whyte, W. A. *et al.* Master transcription factors and mediator establish super-
1296 enhancers at key cell identity genes. *Cell* **153**, 307-319,
1297 doi:10.1016/j.cell.2013.03.035 (2013).
- 1298 37 Davoli, T. *et al.* Cumulative haploinsufficiency and triplosensitivity drive
1299 aneuploidy patterns and shape the cancer genome. *Cell* **155**, 948-962,
1300 doi:10.1016/j.cell.2013.10.011 (2013).
- 1301 38 Kunchala, P., Kuravi, S., Jensen, R., McGuirk, J. & Balusu, R. When the good
1302 go bad: Mutant NPM1 in acute myeloid leukemia. *Blood Rev* **32**, 167-183,
1303 doi:10.1016/j.blre.2017.11.001 (2018).
- 1304 39 Ziai, J. M., Siddon, A. J., Education Committee of the Academy of Clinical
1305 Laboratory, P. & Scientists. Pathology Consultation on Gene Mutations in
1306 Acute Myeloid Leukemia. *Am J Clin Pathol* **144**, 539-554,
1307 doi:10.1309/AJCP77ZFPUGGYGWY (2015).
- 1308 40 Sportoletti, P. *et al.* Npm1 is a haploinsufficient suppressor of myeloid and
1309 lymphoid malignancies in the mouse. *Blood* **111**, 3859-3862,
1310 doi:10.1182/blood-2007-06-098251 (2008).
- 1311 41 Hirsch, S. *et al.* Circular RNAs of the nucleophosmin (NPM1) gene in acute
1312 myeloid leukemia. *Haematologica* **102**, 2039-2047,
1313 doi:10.3324/haematol.2017.172866 (2017).
- 1314 42 Messina, M. *et al.* Genetic lesions associated with chronic lymphocytic
1315 leukemia chemo-refractoriness. *Blood* **123**, 2378-2388, doi:10.1182/blood-
1316 2013-10-534271 (2014).
- 1317 43 de Bock, C. E. *et al.* The Fat1 cadherin is overexpressed and an independent
1318 prognostic factor for survival in paired diagnosis-relapse samples of precursor
1319 B-cell acute lymphoblastic leukemia. *Leukemia* **26**, 918-926,
1320 doi:10.1038/leu.2011.319 (2012).
- 1321 44 Erceg, J. *et al.* Dual functionality of cis-regulatory elements as developmental
1322 enhancers and Polycomb response elements. *Genes Dev* **31**, 590-602,
1323 doi:10.1101/gad.292870.116 (2017).
- 1324 45 Rao, S. S. *et al.* A 3D map of the human genome at kilobase resolution
1325 reveals principles of chromatin looping. *Cell* **159**, 1665-1680,
1326 doi:10.1016/j.cell.2014.11.021 (2014).
- 1327 46 Cao, F. *et al.* Super-Enhancers and Broad H3K4me3 Domains Form Complex
1328 Gene Regulatory Circuits Involving Chromatin Interactions. *Sci Rep* **7**, 2186,
1329 doi:10.1038/s41598-017-02257-3 (2017).
- 1330 47 Shimokawa, T. *et al.* Involvement of the FGF18 gene in colorectal
1331 carcinogenesis, as a novel downstream target of the beta-catenin/T-cell factor
1332 complex. *Cancer Res* **63**, 6116-6120 (2003).
- 1333 48 Jeon, E. *et al.* Investigating the role of FGF18 in the cultivation and
1334 osteogenic differentiation of mesenchymal stem cells. *PLoS One* **7**, e43982,
1335 doi:10.1371/journal.pone.0043982 (2012).
- 1336 49 Constancia, M. *et al.* Placental-specific IGF-II is a major modulator of
1337 placental and fetal growth. *Nature* **417**, 945-948, doi:10.1038/nature00819
1338 (2002).
- 1339 50 Ravenel, J. D. *et al.* Loss of imprinting of insulin-like growth factor-II (IGF2)
1340 gene in distinguishing specific biologic subtypes of Wilms tumor. *J Natl*
1341 *Cancer Inst* **93**, 1698-1703, doi:10.1093/jnci/93.22.1698 (2001).
- 1342 51 Bruecher-Encke, B., Griffin, J. D., Neel, B. G. & Lorenz, U. Role of the
1343 tyrosine phosphatase SHP-1 in K562 cell differentiation. *Leukemia* **15**, 1424-
1344 1432, doi:10.1038/sj.leu.2402214 (2001).

- 1345 52 Huang, R. *et al.* Megakaryocytic differentiation of K562 cells induced by PMA
1346 reduced the activity of respiratory chain complex IV. *PLoS One* **9**, e96246,
1347 doi:10.1371/journal.pone.0096246 (2014).
- 1348 53 Ma, Y. N. *et al.* Emodin can induce K562 cells to erythroid differentiation and
1349 improve the expression of globin genes. *Mol Cell Biochem* **382**, 127-136,
1350 doi:10.1007/s11010-013-1726-3 (2013).
- 1351 54 Dulk, M. *et al.* The scaffold protein Tks4 is required for the differentiation of
1352 mesenchymal stromal cells (MSCs) into adipogenic and osteogenic lineages.
1353 *Sci Rep* **6**, 34280, doi:10.1038/srep34280 (2016).
- 1354 55 Ogino, T., Kobuchi, H., Fujita, H., Matsukawa, A. & Utsumi, K. Erythroid and
1355 megakaryocytic differentiation of K562 erythroleukemic cells by
1356 monochloramine. *Free Radic Res* **48**, 292-302,
1357 doi:10.3109/10715762.2013.865840 (2014).
- 1358 56 Barroca, V., Lewandowski, D., Jaracz-Ros, A. & Hardouin, S. N. Paternal
1359 Insulin-like Growth Factor 2 (Igf2) Regulates Stem Cell Activity During
1360 Adulthood. *EBioMedicine* **15**, 150-162, doi:10.1016/j.ebiom.2016.11.035
1361 (2017).
- 1362 57 Barroca, V., Lewandowski, D., Jaracz-Ros, A. & Hardouin, S. N. Paternal
1363 Insulin-like Growth Factor 2 (Igf2) Regulates Stem Cell Activity During
1364 Adulthood. *EBioMedicine* **15**, 150-162, doi:10.1016/j.ebiom.2016.11.035
1365 (2017).
- 1366 58 Li, G. *et al.* Extensive promoter-centered chromatin interactions provide a
1367 topological basis for transcription regulation. *Cell* **148**, 84-98,
1368 doi:10.1016/j.cell.2011.12.014 (2012).
- 1369 59 Kieffer-Kwon, K. R. *et al.* Interactome maps of mouse gene regulatory
1370 domains reveal basic principles of transcriptional regulation. *Cell* **155**, 1507-
1371 1520, doi:10.1016/j.cell.2013.11.039 (2013).
- 1372 60 Jin, F. *et al.* A high-resolution map of the three-dimensional chromatin
1373 interactome in human cells. *Nature* **503**, 290-294, doi:10.1038/nature12644
1374 (2013).
- 1375 61 Donaldson-Collier, M. C. *et al.* EZH2 oncogenic mutations drive epigenetic,
1376 transcriptional, and structural changes within chromatin domains. *Nat Genet*
1377 **51**, 517-528, doi:10.1038/s41588-018-0338-y (2019).
- 1378 62 Bonev, B. *et al.* Multiscale 3D Genome Rewiring during Mouse Neural
1379 Development. *Cell* **171**, 557-572 e524, doi:10.1016/j.cell.2017.09.043 (2017).
- 1380 63 Rhodes, J. D. P. *et al.* Cohesin Disrupts Polycomb-Dependent Chromosome
1381 Interactions in Embryonic Stem Cells. *Cell Rep* **30**, 820-835 e810,
1382 doi:10.1016/j.celrep.2019.12.057 (2020).
- 1383 64 Huang, J. *et al.* Dissecting super-enhancer hierarchy based on chromatin
1384 interactions. *Nat Commun* **9**, 943, doi:10.1038/s41467-018-03279-9 (2018).
- 1385 65 Boija, A. *et al.* Transcription Factors Activate Genes through the Phase-
1386 Separation Capacity of Their Activation Domains. *Cell* **175**, 1842-1855 e1816,
1387 doi:10.1016/j.cell.2018.10.042 (2018).
- 1388 66 Sanulli, S. *et al.* HP1 reshapes nucleosome core to promote phase separation
1389 of heterochromatin. *Nature* **575**, 390-394, doi:10.1038/s41586-019-1669-2
1390 (2019).
- 1391 67 Maston, G. A., Evans, S. K. & Green, M. R. Transcriptional regulatory
1392 elements in the human genome. *Annu Rev Genomics Hum Genet* **7**, 29-59,
1393 doi:10.1146/annurev.genom.7.080505.115623 (2006).

1394 68 Roadmap Epigenomics, C. *et al.* Integrative analysis of 111 reference human
1395 epigenomes. *Nature* **518**, 317-330, doi:10.1038/nature14248 (2015).
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406